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1Department of Medical Microbiology and Immunology, University of California, Davis, Davis, CA, United States, 2MIND
Institute, UC Davis Medical Center, Sacramento, CA, United States
Autism spectrum disorders (ASD) are a group of heterogeneous neurological disorders
that are highly variable and are clinically characterized by deficits in social interactions,
communication, and stereotypical behaviors. Prevalence has risen from 1 in 10,000 in
1972 to 1 in 59 children in the United States in 2014. This rise in prevalence could
be due in part to better diagnoses and awareness, however, these together cannot
solely account for such a significant rise. While causative connections have not been
proven in the majority of cases, many current studies focus on the combined effects
of genetics and environment. Strikingly, a distinct picture of immune dysfunction has
emerged and been supported by many independent studies over the past decade. Many
players in the immune-ASD puzzle may be mechanistically contributing to pathogenesis
of these disorders, including skewed cytokine responses, differences in total numbers
and frequencies of immune cells and their subsets, neuroinflammation, and adaptive and
innate immune dysfunction, as well as altered levels of immunoglobulin and the presence
of autoantibodies which have been found in a substantial number of individuals with
ASD. This review summarizes the latest research linking ASD, autoimmunity and immune
dysfunction, and discusses evidence of a potential autoimmune component of ASD.
Keywords: autism, immune, dysregulation, autoimmunity, neurodevelopment, behavior
INTRODUCTION
First defined as a distinct syndrome in 1943 by child psychiatrist Kanner (1943), autism
spectrum disorders (ASD) are a group of heterogeneous neurological disorders that are clinically
characterized by deficits in social interactions, communication, and stereotypical behaviors (Baio
et al., 2018). Recent prevalence of ASD has risen dramatically to 1-in-59 US children, with
preponderance toward males (Baio et al., 2018). Although increased awareness of the disorder
and changing diagnostic criteria have undoubtedly contributed to the increase in prevalence (King
and Bearman, 2009), researchers agree that these cannot solely account for such a significant
rise in occurrence (Hertz-Picciotto and Delwiche, 2009). While the cause of the majority of ASD
remains elusive, it likely involves a combination of genetic, epigenetic, and environmental factors.
Twin studies have found a high concordance rate among monozygotic twins, with a much lower
rate among dizygotic twins, implicating genetics as a factor; however, when combined, genetic
interactions/mechanisms account for only 10–20% of ASD cases (Abrahams andGeschwind, 2008),
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this may suggest other heritable factors or shared genetic
and environmental influences may be involved. These genetic
markers may also be present in healthy individuals, again
suggesting other risk factors in the pathogenesis of most cases
of ASD. The rate for dizygotic twins is higher than non-twin
siblings, and may suggest that shared prenatal environmental
factors such as maternal infection, diet, and household chemical
exposures may play a significant role in the etiology of
ASD (Hallmayer et al., 2011). Environmental factors during
pregnancy including maternal inflammation, air pollution and
pesticide exposure have been associated with an increased risk
of developing ASD and could be responsible for epigenetic
changes identified in ASD (Loke et al., 2015); however, no single
etiological factor has risen to the forefront. Research in ASD
is confounded by the fact that these are highly heterogeneous
disorders that likely have multiple etiologies and converging
pathophysiological pathways. There is a growing need to
determine which factors might be involved in the development
of these disorders, as individuals with ASD and their families
experience increased stress and decreased quality of life (Estes
et al., 2013; Kuhlthau et al., 2014), and the increased prevalence
of ASD has created a significant burden on health care (Lavelle
et al., 2014) with an economic impact projected to exceed $400
billion by 2025 (Leigh and Du, 2015).
Although the specific etiologies of ASD remain unknown,
many hypotheses regarding causation of ASD abound, including
the potential involvement of the immune system. Just over
a decade ago, we hypothesized that ASD may in fact be an
autoimmune disorder (Ashwood and Van de Water, 2004;
Ashwood et al., 2006). At that time, immune studies were
limited and results had been somewhat inconsistent between
various laboratories. Since then, a significant amount of research
linking ASD and aberrant immune function has taken place,
and although inconsistencies still exist, a clearer picture of
the importance of immune involvement in ASD has emerged.
This comprehensive review summarizes the latest research
linking ASD and immune dysfunction, and discusses evidence of
potential autoimmune mechanisms of ASD.
FAMILIAL AUTOIMMUNITY
Diverse autoimmune diseases within a nuclear family suggest
familial autoimmunity (Anaya et al., 2007). Historically, studies
have shown an increased prevalence of familial autoimmune
disorders in ASD. The first study to identify a connection
was in 1971, where researchers found a child with ASD
who had several family members with multiple autoimmune
disorders (Money et al., 1971). A later study found that
46% of ASD families had two or more members with
autoimmune disorders, and as the number of autoimmune
disorders within the family rose from one to three, the
odds ratio for a risk of a child with ASD increased from
1.9 to 5.5. This study found that autoimmune prevalence
was significantly increased in mothers and first-degree family
members of ASD subjects, with type I diabetes (T1DM),
rheumatoid arthritis (RA), hypothyroid and systemic lupus
erythematosis (SLE) being the most common disorders found
(Comi et al., 1999). A 2003 study also found a specific link
to hypothyroid/Hashimoto’s thyroiditis and RA in parents with
ASD offspring (Sweeten et al., 2003a); however, others only
found such an increase was paternally linked (Micali et al.,
2004).
Since then, both self-reported and registry-based studies
have shown additional links to autoimmunity in the family
of children with ASD. A study in 2006 found autoimmune
thyroid disease to be a significant risk factor, especially if
the family member was the mother (Molloy et al., 2006a).
This and other self-reported studies have some limitations
as they may include biased or inaccurate recall. Utilization
of health registries have allowed researchers to obtain larger
datasets from patients based on medical records in population
based case-control studies. In 2007, Mouridsen et al. found
maternal ulcerative colitis and paternal T1DM were associated
with infantile autism, (Mouridsen et al., 2007). In addition,
mothers with autoimmunity were more likely to have a child
with intellectual disability (ID), defined as an IQ of less than
50 (Mouridsen et al., 2007). In a large nationwide study that
included all children born in Denmark from 1993 to 2004
(689,196 children, 3325 with ASD), researchers found that
maternal RA and celiac disease increased risk of ASD in offspring
(RA incidence rate ratio (IRR): 1.70 [95% CI: 1.07–2.54]; celiac
disease IRR: 2.97 [95% CI: 1.27–5.75]), and an increased risk of
infantile autism was found to be associated with family history of
T1DM in either parent [IRR:1.78; 95% CI:1.16–2.61] (Atladottir
et al., 2009). A further study utilizing the Danish registries looked
specifically at both maternal and paternal RA and risk for ASD
through 2007. Their data show that the risk of ASD increased
by approximately 30% in cases of parental RA (maternal: HR
1.31 and 95% CI 1.06–1.63; paternal: HR 1.33, 95% CI 0.97–
1.82). They conclude that a genetic component, specifically the
Human Leukocyte Antigen − antigen D Related (HLA−DR)
B1∗04 alleles found commonly in both RA and ASD, may be
playing a significant role in the development of ASD along with
environmental factors (Rom et al., 2018). Registry-based studies
have also shown an almost 50% higher odds-ratio of a child
having an ASD diagnosis by age 10 if either parent had any
autoimmune disease (maternal OR =1.6 [95% CI = 1.1–2.2];
paternal OR = 1.4 [95% CI = 1.0–2.0]), with maternal T1DM,
idiopathic thrombocytopenic purpura (ITP), myasthenia gravis
and rheumatic fever carrying the highest risks (Keil et al., 2010).
Confirming the link to autoimmune thyroid disorders
previously found in case reports, a nested case control study
in Finland identified a significantly increased risk of developing
ASD in children who were born to mothers positive for anti-
thyroid peroxidase antibodies (TPO-Ab+) during pregnancy.
This study looked at a population of children born in Finland
between 1987 and 2005, which included 1,132 confirmed cases
of childhood autism. When compared to 967 matched controls,
they found odds for developing ASD without ID were increased
nearly 80% among children born to mothers who were TPO-
Ab+ during pregnancy (OR = 1.78, 95% CI = 1.16–2.75).
Interestingly, the odds were not increased for development of
ASD with comorbid ID (Brown et al., 2015).
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These large population studies rely on medical reporting and
abstraction of medical data, as well as only reporting past and
present autoimmunity, therefore they may not cover younger
mothers who develop autoimmunity after the study period has
ended. Nonetheless, a consistent pattern has emerged, as multiple
meta-analyses have confirmed the familial autoimmunity and
ASD link. A 2016 meta-analysis of mainly cased-control studies
found significant positive associations of ASD with maternal
autoimmunity during pregnancy (pooled OR: 1.34, 95% CI 1.23–
1.56) and maternal autoimmune thyroid conditions (pooled OR:
1.29, 95% CI 1.14–1.45) (Chen et al., 2016). Familial T1DM and
autoimmune thyroid disease were also associated with higher
rates of regressive autism, versus those with developmental delays
evident during infancy (Scott et al., 2017). Overall, combined
family history of autoimmune disorders increased the risk of
ASD by 28%, withmost significant increased risks associated with
psoriasis 59%, RA 51%, T1DM 49%, and hypothyroid 64% (Wu
et al., 2015)].
In summary, the results of these familial studies do not single
out one autoimmune disease and risk for ASD; however, a clear
familial autoimmune component has emerged. The significant
overlap of autoimmunity within the family members of ASD
subjects may suggest an involvement of inherited immune
factors. Maternal autoimmunity could also be playing a role
in the gestational immune environment that has been found
to significantly influence neurodevelopment. Summary of these
studies can be found in Table 1.
GESTATIONAL IMMUNE INFLUENCES
Maternal Autoantibodies
The gestational environment is protected by the placenta, a
selective barrier that allows for nutrient uptake and waste
elimination, and provides protection from pathogens while
allowing protective immune factors such as immunoglobulin-G
(IgG) to cross into the amniotic fluid compartment (Garty et al.,
1994). This passage could be facilitating the transfer of maternal
IgG that target fetal brain antigens and could play an etiological
role in ASD by blocking or activating proteins in the fetal brain,
or initiating a cascade of neuroinflammation. In addition to
an increased prevalence of familial and maternal autoimmunity
in ASD, a subset of mothers of children with ASD (10–12%)
have been found to harbor autoantibodies with reactivity to fetal
brain components (summarized in Table 2), and these antibodies
induce ASD-like pathology in animal models (Martin et al., 2008;
Braunschweig et al., 2012b; Bauman et al., 2013).
The first evidence of such antibodies was found in 2003
in the serum of a mother with two children on the autism
spectrum. These antibodies were found to be reactive to Purkinje
cells and other neuronal proteins in rodent brain tissue (Dalton
et al., 2003). Since then, several studies have identified maternal
antibodies with reactivity to various brain proteins of different
molecular weights in mothers of ASD subjects. For example,
Zimmerman et al. found multiple patterns of reactivity to rat
brain proteins of low kilodalton (kDa) weight, and one at 250
kDa (Zimmerman et al., 2007). When measured by Western
blot for reactivity to human and rodent fetal brain tissue,
sera from ASD mothers had significant reactivity to a 36 kDa
protein present in both human and rodent fetal brain and
dense banding at 61 kDa (Singer et al., 2008). Braunschweig
et al. observed immunoreactivity to proteins at approximately
37 and 73 kDa exclusively in the mothers of children with
ASD, and found these to be associated with increased language
deficits in the child. Additional reactivity to a pair of bands
in the region of 39 and 73 kDa was associated with increased
irritability and self-injurious behavior (Braunschweig et al., 2008,
2012a). Multiple studies have since confirmed the presence of
maternal autoantibodies (MAbs) with paired reactivity to 37 and
73 kDA proteins exclusive to mothers of children with ASD
(Croen et al., 2008; Nordahl et al., 2013; Rossi et al., 2013).
Consistent with these studies, Piras et al. found that single
(or combinations of) maternal anti-brain antibodies correlated
with severity of language and other behavioral impairments,
and that the presence of a specific autoantibody at 62 kDa in
the child correlated with the presence of autoantibodies in the
mother (Piras et al., 2014). Brimberg et al. confirmed that anti-
brain antibodies are significantly more prevalent in mothers
of children with ASD than typically developing children, and
a majority of these women who harbor anti-brain antibodies
also harbor anti-nuclear antibodies common to autoimmune
disorders (Brimberg et al., 2013). Although the presence of these
maternal autoantibodies were associated with risk of ASD in
offspring, these studies are limited in that no clear mechanism
was identified, which limits our understanding of how theymight
contribute to the etiology of ASD.
Animalmodels have allowed us to identify some pathogenicity
of these autoantibodies (Table 3). Passive transfer of anti-brain
antibodies from mothers of children with ASD to animals
during gestation led to ASD-like pathology in both rodent
(Singer et al., 2009; Braunschweig et al., 2012b) and primate
offspring (Martin et al., 2008; Bauman et al., 2013), Target
antigens to these maternal autoantibodies have since been
identified as lactate dehydrogenase A and B (LDH−37 kDa
band), cypin (previously undetected 44 kDa band), stress-
induced phosphoprotein 1 (STIP1-upper 73 kDa band), collapsin
response mediator proteins 1 and 2 (CRMP1/2-lower 70 kDa
band) and Y-box-binding protein (YBX1–39 kDa band), with
individual and combinations of maternal autoantibodies specific
to these antigens increased in mothers of children with ASD.
Increased stereotypical behavior and overall impairment were
observed in children of mothers who possessed combinations
of these autoantibodies (Braunschweig et al., 2013). Using
structural magnetic resonance imaging (MRI), Nordahl et al.
showed enlarged brain volume in male children born to mothers
harboring anti-brain antibodies (Nordahl et al., 2013). In rodents,
maternal autoantibodies administered during gestation were
found to be able to migrate into the cortical parenchyma and
alter coronal development by binding to radial glial cells in the
ventricular zone and increased the number of neuronal precursor
cells in the subventricular zone, increasing brain size and weight.
Administration of autoantibodies also led to decreased numbers
of mature dendritic spines in the adult cortex of mice, with
STIP1 blockade being the likely culprit due to its importance
in neuritogenesis, the sprouting of neurites that later develop
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TABLE 1 | Studies identifying association of familial autoimmunity and ASD.
Subject details Methods Summarized findings References
61 ASD
46 TD
Self-reported questionnaire: known AI
within family
46% ASD families had 2+ members with AI
↑ ASD odds ratio (1.9 to 5.5) as number of family members with AI
↑ from 1-3
↑ T1DM, RA, hypothyroid and SLE in ASD mothers and 1st
degree relatives
Comi et al., 1999
101 ASD
101 AI
101 HC
Self-reported questionnaire: which
1st and 2nd degree relatives have AI
↑ frequency of AI in ASD families compared to AI and TD families
↑ AI including hypothyroid/Hashimoto’s thyroiditis and RA in ASD
parents
Sweeten et al., 2003a
79 ASD
61 DD
Self-reported questionnaire: ASD with
familial AI and psychiatric history
No significant relationship of AI in ASD vs. DD
31.5% of ASD fathers vs 18.2% control had AI
No difference found in mothers.
Micali et al., 2004
153 ASD
155 regressive
ASD
Telephone interview: AI in 1st and 2nd
degree relatives.
ASD with regression ↑ in families with 1st or 2nd degree AI
relatives
↑ risk with familial AI thyroid diagnoses, especially maternal family
members
Molloy et al., 2006a
111 ASD
330 TD
Registry based: Danish national
hospital registry
↑ risk of ASD with maternal UC and paternal T1DM
Mothers with AI more likely to have child with ID (IQ < 50)
Mouridsen et al., 2007
3325 ASD (1089
“infantile autism”)
Registry based: all children born in
Denmark 1993–2004
↑ risk of ASD with maternal RA and celiac disease
↑ risk of infantile autism associated with family history of T1DM,
both parents.
Atladottir et al., 2009
1227 ASD
30,675 TD
Registry based: Three Swedish
registries
↑ risk of ASD with AI in both parents
↑ risk of ASD with maternal T1DM, ITP, myasthenia gravis and
rheumatic fever
Keil et al., 2010
967 ASD
967 TD
Nested case–control design:
prospectively drawn maternal sera
samples with registry-based ASD
diagnoses from FiPS-A
↑ risk of ASD with maternal TPO-Ab presence during pregnancy Brown et al., 2015
11 studies Systematic review and meta-analysis ↑ risk of ASD with family history of all AI
↑ risk of ASD with familial hypothyroidism, RA, and psoriasis
Wu et al., 2015
10 studies Systematic review and meta-analysis ↑ risk of ASD with maternal AI developed during pregnancy
↑ risk of ASD with maternal thyroid disease
Chen et al., 2016
206 ASD
33 regressive ASD
Medical chart review of ASD
diagnosis and familial AI association
↑ risk of regressive ASD with familial AI
Regressive ASD associated with familial T1DM and autoimmune
thyroiditis
Scott et al., 2017
ASD, autism spectrum disorders; TD, typically developing; AI, autoimmunity; T1DM, Type 1 diabetes mellitus; RA, rheumatoid arthritis; C: SLE, systemic lupus erythematosus; healthy
control; BAP, broad autism phenotype; IBD, inflammatory bowel disease; UC, ulcerative colitis; ID, intellectual disability; ITP, idiopathic thrombocytopenic purpura; FiPS-A, Finnish
Prenatal Study of Autism; TPO-Ab, thyroid peroxidase antibody.
into dendrites (Martinez-Cerdeno et al., 2016; Ariza et al., 2017).
Mice exposed to maternal autoantibodies during the embryonic
stage displayed ASD-like behaviors including increased repetitive
behaviors and altered social interactions (Camacho et al., 2014).
Generation of endogenous autoantibodies prior to gestation to
the fetal brain epitopes identified in ASD mothers also led
to social deficits and increased repetitive grooming in adult
offspring mice (Jones et al., 2018).
Although the origin(s) of these autoantibodies are unknown,
they are more frequent in mothers carrying a functional
variant of the Met Receptor Tyrosine Kinase (MET) promoter
which leads to reduced production of MET receptor tyrosine
kinase, a receptor involved in immune regulation (Heuer
et al., 2011). Mothers carrying the variant MET allele had
reduced interleukin (IL)-10, an important regulatory cytokine,
suggesting that dysfunction in immune regulation may be
driving the production of autoantibodies (Heuer et al., 2011).
Understanding the development of these MAbs and the role of
the proteins they target in neurodevelopment is important due
to the substantial number of ASD cases found to involve these
antibodies. Research in this area may lead to diagnostic tools
that assess maternal risk, as well as possible treatments and early
interventions for children with maternal autoantibody-related
ASD.
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TABLE 2 | Studies identifying presence of anti-brain autoantibodies in mothers of children with ASD.
Subject details Methods Summarized findings References
Mother with 2 ASD
children
IHC of sera binding to rodent brain. Pilot study-maternal sera had reactivity to rodent Purkinje cells in
cerebellum and large brain stem neurons.
Dalton et al., 2003
11 ASD mothers
10 TD mothers
Serum reactivity to prenatal,
postnatal, and adult rat brain proteins
by immunoblotting
↑ reactivity to prenatal rat brain in multiple patterns of low kDa
weight, and one significantly higher at 250 kDa
No reactivity to postnatal or adult rat brain
Zimmerman et al.,
2007
100 ASD mothers
100 TD mothers
Serum reactivity to human and rodent
fetal and adult brain tissues, GFAP,
and MBP by immunoblotting
↑ reactivity at 36 kDa in both human fetal and rodent embryonic
brain tissue.
↑ reactivity at 61 kD in human fetal brain tissue.
↑ reactivity at 36 and 39 kDa against human fetal brain in mothers
whose children had regressive ASD.
Singer et al., 2008
61 ASD mothers
62 TD mothers
40 DD mothers
Plasma reactivity to human fetal and
adult brain proteins by
immunoblotting
↑reactivity to 73kDa and 37kDa to human fetal brain correlated
with regressive ASD
Reactivity to 37 kDa was higher in ASD mothers compared with
TD and DD mothers.
No reactivity with TD plasma to either tissue type.
Braunschweig et al.,
2008
84 ASD mothers
49 DD mothers
160 TD mothers
Mid-pregnancy plasma reactivity to
fetal brain protein by immunoblotting
↑reactivity at 39 kDa in ASD compared to DD and TD
Reactivity at both 39 kDa and 73 kDa seen only in early-onset ASD
Croen et al., 2008
202 ASD mothers
163 TD mothers
PCR for MET rs1858830 allele
genotyping. Measured MET protein
and cytokines by Luminex from
stimulated maternal PBMCs. Previous
study results used for the
associations to presence of auto-Abs
Presence of C allele associated with reactivity at 37 and 73-kDa to
fetal brain proteins.
Presence of C allele associated with ↓ MET protein expression
and ↓ IL-10
Heuer et al., 2011
277 ASD (70 BAP)
189 age-matched
TD (2-5 years) and
their mothers
Maternal plasma reactivity to Rhesus
macaque fetal brain protein medleys
by immunoblotting, child plasma
reactivity to Rhesus macaque
cerebellum protein medley.
↑ reactivity to many including proteins with MW of 42, 49, 60, 80,
and 100 kDa in plasma from ASD mothers
No correlation with reactivity found in children
Child results listed in Table 4.
Goines P. et al., 2011
204 ASD mothers
71 BAP mothers
102 DD mothers
183 TD mothers
Maternal plasma reactivity to Rhesus
macaque brain at 3 gestational ages
by immunoblotting
↑ paired reactivity at 37 and 73 kDa combined in ASD, not seen in
TD
↑ paired reactivity at 39 and 73 kDa in ASD and BAP compared to
TD and DD
Paired reactivity at 37 and 73 kDa associated with language
deficits.
Paired reactivity at 39 and 73 kDa associated with increased
irritability
Reactivity to 39 kDa (alone or paired with 73 kDa) associated with
BAP
Braunschweig et al.,
2012a
37 ASD and TD
mothers
and their children
ages 3-13 years
IHC for plasma reactivity to rhesus
macaque brain tissue. Immunoblot
reactivity to fetal and adult rhesus
macaque brain proteins.
Reactivity at 37 and 73 kDa or 39 and 73 kDa found only in ASD
mothers
No significant differences in reactivity seen in ASD children vs. TD.
Rossi et al., 2013
Preschool aged
males: 131 ASD
(10 with 37/73 kDa
IgG+ mothers)
50 TD, all negative
for auto-Abs
MRI scan (during sleep) to evaluate
total brain volume and compare
maternal auto-Ab positive group to
maternal auto-Ab negative groups
↑ abnormal brain enlargement in ASD, both groups
ASD children with 37/73 kDa IgG+ mothers had more extreme
abnormal brain enlargement compared to Ab negative ASD and
TD groups, specifically in the frontal lobe.
Nordahl et al., 2013
(Continued)
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TABLE 2 | Continued
Subject details Methods Summarized findings References
246 ASD mothers
149 TD mothers
Plasma reactivity to fetal macaque
brain verified by immunoblotting.
Protein enrichment via PlasmPrep cell
protein fractionation, 2-D
electrophoresis and mass
spectrometry.
6 brain proteins that has plasma reactivity were identified: lactate
dehydrogenase A and B (LDH), cypin, stress-induced
phosphoprotein 1 (STIP1), collapsin response mediator proteins 1
and 2 (CRMP1, CRMP2) and Y-box-binding protein (YBX1)
Reactivity to any alone or in combination significantly was
associated with ASD outcome
↑ stereotypical associated with reactivity to LDH, and combined
reactivity to LDH/STIP1 or LDH/STIP1/CRMP1
↑ overall impairment associated with reactivity to LDH and CRMP1
Braunschweig et al.,
2013
2431 ASD
mothers, 653
controls of
child-bearing age
Plasma IHC reactivity to mouse brain ↑ presence of brain-reactive auto-Abs in ASD mothers compared
to control women
Presence of brain-reactive auto-Abs associated with anti-nuclear
autoantibodies and increased prevalence of autoimmune
diseases, especially RA and SLE.
Brimberg et al., 2013
333 ASD mothers
355 ASD
142 SIB
Child and mother plasma reactivity to
Rhesus macaque brain tissue and
human adult cerebellum by
immune-blotting
Reactivity at 37, 39 and/or 73 kDa anti-brain auto-Abs associated
with impaired language development, neurodevelopmental delay
and sleep/wake cycle disturbances.
Presence of the 62 kDa autoAb in the child associated with
maternal reactivity at 39 and/or 73 kDa.
Child results listed in Table 4.
Piras et al., 2014
ASD, autism spectrum disorders; IHC, immunohistochemistry; TD, typically developing; kDa, kilodalton; GFAP, glial fibrillary acidic protein; MBP, myelin basic protein; DD, non-ASD
developmentally delayed; PCR, polymerase chain reaction; PBMC, peripheral blood mononuclear cells; BAP, broader diagnosis of autism spectrum disorder; IgG, immunoglobulin G;
MRI, magnetic resonance imaging; 2-D, two dimensional; auto-Abs, auto-antibodies; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SIB, typically developing sibling.
Maternal Immune Activation (MIA)
Maternal infection during pregnancy has been implicated as
a potential environmental risk factor for ASD (reviewed in
Patterson, 2011). In case series reports, infections during
pregnancy, such as rubella, measles or toxoplasmosis, can
negatively impact early neurodevelopment of the fetus. In
population based studies, viral, and bacterial infections occurring
in the first or third trimester, respectively, or maternal fever
during gestation pose an increased risk for later development
of ASD in offspring (Atladottir et al., 2010; Zerbo et al.,
2013). Both rodent and non-human primate models of maternal
infection during gestation have supported epidemiological
studies, showing alterations in ASD-associated behaviors and
immune dysregulation that persisted into adulthood in offspring
born to mothers exposed to viral or bacterial antigens during
gestation (Schwartzer et al., 2013; Bauman et al., 2014; Meyer,
2014; Onore et al., 2014; Choi et al., 2016; Rose et al., 2017).
Maternal asthma during pregnancy has also previously been
linked with ASD (Croen et al., 2005; Lyall et al., 2014).
Furthermore, in a cohort of 220 children with ASD, those
whose mothers had a history of allergies or asthma during
pregnancy displayed more severe social impairments (Patel
et al., 2017). Animal models of maternal gestational asthma
have validated both behavioral and immune abnormalities in
offspring, including epigenetic alterations in methylation of
immune pathway genes in microglia–the resident immune cells
of the brain (Schwartzer et al., 2015, 2017; Vogel Ciernia et al.,
2018).
The driving mediators of MIA-associated ASD pathology are
most likely elevations in maternal cytokines and chemokines.
In addition to their roles as immune-mediators, these signaling
proteins play important roles in central nervous system (CNS)
development and are involved in migration of neuronal
precursors, neuronal maintenance, synaptic pruning and
plasticity, thus they need to be tightly regulated (Deverman
and Patterson, 2009). Cytokines that cross the placenta, such as
IL-6 and IL-4, have the potential to alter epigenetic regulation
of gene transcription (Nardone and Elliott, 2016). Elevations
of cytokines and chemokines in both maternal serum during
gestation and amniotic fluid are associated with increased risk of
ASD in human subjects (Goines P. E. et al., 2011; Abdallah et al.,
2012; Jones et al., 2016). Mechanistically, maternal cytokines
such as IL-6 and IL-17 may be mediating inflammation either
at the placenta or directly in the developing fetal brain (Smith
et al., 2007; Hsiao et al., 2012; Choi et al., 2016). Moreover, it is
possible that maternal inflammation may be contributing to the
development of maternal autoantibodies (Figure 1). As well as
cytokine driven responses, other downstream events occur that
can effect immune and neuronal development. For instance, in
the LPS model of MIA trace metal levels are altered included the
sequestration of zinc in both the dams and offspring (Coyle et al.,
2009; Kirsten et al., 2015; Kirsten and Bernardi, 2017).
Recent evidence in a mouse model of MIA suggest that
maternal microbiota composition may be driving maternal
inflammation to skew toward IL-17 production, inducing
behavioral changes. Dams lacking certain microbiota did not
produce IL-17 and their offspring did not exhibit aberrant
behavioral phenotypes. IL-17 blockade was also effective in
preventing behavioral abnormalities (Choi et al., 2016; Kim et al.,
2017). This is a notable finding considering our understanding
of IL-17 as a central driver of autoimmune disorders (Zhu and
Qian, 2012). A better understanding of the role of IL-17 signaling
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TABLE 3 | Preclinical studies of maternal autoantibodies and ASD-like pathology.
Pre-clinical model details Summarized findings References
Mouse model
Sera from 1 ASD mother (auto-Ab+) and 4 TD mothers injected into
pregnant MF1 mice at varied time points. Offspring behaviors and
cerebellar chemistry measured with standard behavioral tests and MRS
ASD-sera exposed offspring exhibited:
↓ reflexes
↓ exploration
↓ spatial orientation
↓ creatine and choline concentrations in cerebellum
No impairments in memory
Dalton et al., 2003
Non-human primate model
Purified IgG from separately pooled from 21 ASD and 7 TD maternal
sera, measured for presence of auto-Abs. 4 Rhesus macaques were
injected IV with auto-Ab+ IgG from ASD maternal sera and 4 were
injected with auto-Ab- IgG from TD maternal sera at GD 27, 41, and
55. Behaviors assessed at preweaning and postweaning time points.
ASD-IgG exposed offspring exhibited:
↑ whole-body stereotypies
↑hyperactivity
No significant differences seen in social behaviors
Martin et al., 2008
Mouse model
Purified IgG from separately pooled from 63 ASD and 63 TD maternal
sera, injected IP into 26 pregnant C57Bl/6J mice total, 13 dams per
group, at E13-E18. Offspring from untreated and from saline injected
mice included as negative controls. Several behavioral and
neurodevelopmental outcomes measured.
ASD-IgG exposed offspring exhibited:
↑ anxiety, startle, and hyperactivity
↑ Iba1 staining indicating microglia activation in E18 embryos
↑ BDNF at adolescence
Social deficits seen at adulthood
IL-12 detectable in E16 embryos
Singer et al., 2009
Mouse model
Purified IgG from pooled from 3 ASD maternal sera positive for 37 kDa
and 73 kDa fetal brain protein reactivity. Purified IgG also pooled from 3
TD maternal sera absent of reactivity. Single IV injection of purified IgG
per group given to pregnant C57Bl/6J mice at GD 12, saline given as
negative control. Offspring assessed for behavioral abnormalities and
alterations in neurodevelopment.
ASD-IgG exposed offspring exhibited:
↓ weight and body length
↓ sensory and motor development prior to weaning
↑ anxiety
↑ vocalizations during separation-induced stress in males at PND8
Social deficits trended in males but did not reach significance
No differences seen in stereotypical behaviors
No differenced seen in numbers of CA1 hippocampal neurons
Braunschweig et al.,
2012b
Non-human primate model
Purified IgG from ASD maternal sera positive for 37 kDa and 73 kDa
autoAbs and purified IgG from TD maternal sera absent of reactivity
injected IV into two groups of pregnant Rhesus macaques at GD 30,
44, 58, 72, 86, and 100.
ASD-IgG exposed offspring exhibited:
↑ maternal protectiveness during pre-weaning stage
↑ inappropriate and frequency of social approach in juveniles
↑ brain volume in males compared with controls, mainly white
matter and most profoundly in the frontal lobes.
Bauman et al., 2013
Mouse model
Purified IgG from ASD maternal sera positive for autoAbs or from TD
maternal sera absent of reactivity was injected directly into cerebral
ventricles of E14 embryonic Swiss Webster mice. Behaviors measured
with battery of behavioral assays
ASD-IgG injected adult offspring exhibited:
↑ grooming
↑ marble burying
No differences in social approach, however ASD-IgG mice had↑
time spent with novel object compared to mice injected with
TD-IgG
Camacho et al., 2014
Mouse model
Biotinylated IgG from ASD maternal sera positive for 37 kDa and 73
kDa fetal brain protein reactivity or from TD maternal sera absent of
reactivity was injected directly into cerebral ventricles of E14 or E16
embryonic Swiss Webster mice. Brain reactivity and quantification
assessed with IHC and stereology.
Brain from ASD-IgG injected embryos exhibited:
Reactivity to RG cells (neural stem cells) in VZ
↑proliferative Pax6+ RG cells in the SVZ
↑mitotic precursor cells in the SVZ of the ganglionic eminence (a
neurodevelopmental structure that guides cell and axon migration)
RG cells translocated much earlier than control mice
↑ brain weight and rostro-caudal length
↑somal volume in neurons
Martinez-Cerdeno
et al., 2016
Mouse model
Purified IgG from ASD maternal sera positive for 37 kDa and 73 kDa
fetal brain protein reactivity or from TD maternal sera absent of
reactivity was injected directly into cerebral ventricles of E14 embryonic
Swiss Webster mice. Changes in dendritic arbor and spine population
assessed with Golgi method and Neurolucida.
Adult brain from ASD-IgG injected embryos showed:
↓ length and volume of dendritic spines on neurons of the frontal
cortex
↓ total number of spines on neurons in frontal cortex
↓ total number of spines on neurons in occipital cortex
↓ spine density of apical dendrites, and
↓ number of mature spines on basal and apical dendrites in
occipital cortex
Ariza et al., 2017
(Continued)
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TABLE 3 | Continued
Pre-clinical model details Summarized findings References
Mouse model
Mixtures of 21 synthesized epitopes of LDH-A, LDH-B, STIP1, and
CRMP1 (fetal brain target peptides) plus adjuvant were injected SC 5
times into dams prior to mating (MAR-ASD). Control females injected
SC with saline plus adjuvant. Maternal sera tested for verification of
endogenous autoAb production. Offspring behaviors measured with
behavioral assays
Epitope-specific antibodies were successfully produced and
persisted in dams through end of lactation MAR-ASD offspring
exhibited:
↑ weight and head width
↑ repetitive behaviors
↓ social behaviors, including male-female social interactions
Jones et al., 2018
ASD, autism spectrum disorder; autoAb, autoantibody; MRS, magnetic resonance spectroscopy; IgG, immunoglobulin G; TD, typically developing; IV, intravenous; GD, gestational day;
IP, intraperitoneal; Iba1, Ionized calcium binding adaptor molecule 1; E13, embryonic day 13; BDNF, brain derived neurotrophic factor; IL-12, interleukin-12; IHC, immunohistochemistry;
RG cells, radial glial cells; VZ, ventricular zone; SVZ, subventricular zone; LDH, lactate dehydrogenase; STIP1, stress-induced phosphoprotein 1; CRMP1, collapsin response mediator
protein 1; SC, subcutaneous.
FIGURE 1 | Maternal immune influences during gestation increase risk of ASD. Infection and immune-mediated/autoimmune disorders in the mother are known risk
factors that increase the chances of a child developing ASD. These inflammatory factors as well as altered maternal microbiota may be contributing to increased
inflammatory cytokines and/or autoantibodies that react to fetal brain tissue. These factors alter the immune profile and neurodevelopment of the child and are linked
to behavioral abnormalities seen in ASD including repetitive behaviors, stereotypies, anxiety, and impaired social behaviors.
during gestation and within the fetal brain may hopefully lead to
therapeutics targeting this cytokine.
IMMUNE FINDINGS IN INDIVIDUALS WITH
ASD
Immune Mediated Co-morbidities
Among the many immune findings in ASD, several recent
large-scale studies have indicated that individuals with ASD
have frequent immune-mediated comorbid health issues that
may progress or predispose to later-life autoimmune conditions
(Figure 2). Zerbo and colleagues found that allergies and
autoimmunity diagnoses were significantly more common in
children with ASD, with odds ratios of 1.22 and 1.36, respectively
(Zerbo et al., 2015). Children with ASD, as surveyed in the
National Health Interview Survey, require higher health care use
and have a higher prevalence of most medical conditions defined
in autoimmune areas, compared to those without developmental
disabilities (Schieve et al., 2012). However, as many autoimmune
conditions do not manifest until adulthood, the young age of
most study populations is a limitation to finding associations
between ASD and autoimmunity. To determine significant
pathogenic components of ASD, cluster analysis found immune
dysfunction to be the best-defined cluster for ASD. This study
noted that immune dysfunction underlined the majority of
comorbidities observed in ASD (Sacco et al., 2012). Allergic
diseases are overrepresented in ASD, and in some individuals
may influence behaviors and severity of core behavioral deficits
(Mostafa et al., 2008; Shibata et al., 2013). A large epidemiological
study found that asthma was 35% more common in children
with ASD compared to typically developing children (Kotey et al.,
2014). This supports a previous study that found a significantly
increased risk of asthma in ASD subjects, with an odds ratio of
1.74 (Chen et al., 2013). Increased risk of type 1 diabetes, allergic
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 November 2018 | Volume 12 | Article 405
Hughes et al. Immune Dysfunction, Autoimmunity in ASD
FIGURE 2 | Aberrant Immune Findings in Individuals with ASD. Evidence of immune dysfunction in ASD has grown substantially in recent years. Individuals with ASD
commonly have immune-mediated comorbidities such as allergies and gastrointestinal (GI) dysfunction that may be contributing to the aberrant behaviors seen in
ASD. Although research in this area is occasionally contradictory, the vast majority of immune studies in individuals with ASD have shown immune dysfunction and
dysregulation. Several studies have found elevations in inflammatory cells and cytokines, both peripheral as well as within post-mortem brain tissue. A variety of
autoantibodies targeting various tissues and cellular components throughout the body have been identified in subsets of subjects with ASD. Individuals with ASD also
have fewer regulatory T cells.
rhinitis, atopic dermatitis, urticaria and a trend toward increasing
comorbidity with Crohn’s disease are also observed in subjects
with ASD (Chen et al., 2013). The same group looked specifically
at asthma in a nationwide population-based prospective study
over 8 years and found children with asthma in early life had
an increased risk of developing ASD (adjusted hazard ratio: 2.01,
95% confidence interval: 1.19–3.40) (Tsai et al., 2014). An analysis
of over 1500 adults with ASD showed significantly increased
rates of medical conditions in individuals with ASD compared
to non-ASD controls, including but not limited to immune
co-morbidities, gastrointestinal (GI) disorders, diabetes, obesity,
seizures, and sleep disorders (Croen et al., 2015).
One of the most commonly reported comorbidities in ASD
is the incidence of GI dysfunction and inflammation in the
GI tract (Figure 2). Assessment for GI dysfunction is often
challenging in individuals with ASD due to communication
deficits. Reported prevalence of GI disturbances varies widely,
with ranges from 9 to over 90% in ASD subjects; however, the
2013 Interagency Autism Coordinating Committee concluded
that at least 50% of children with ASD had GI issues (discussed
in Mcelhanon et al., 2014). A 2014 assessment of 960 children
enrolled in the Childhood Autism Risks from Genetics and
the Environment (CHARGE) study found that children with
ASD had significantly increased odds of having at least one GI
symptom compared to typically developing controls (OR 7.92
[4.89–12.85]) (Chaidez et al., 2014). Discrepancies in prevalence
rates of GI comorbidities in ASD are likely due to differences
in defining criteria for symptoms, referral bias, variations in
samples sizes and sources of data, as well as the timing in which
symptoms were reported (Buie et al., 2010; Coury et al., 2012).
Early studies examining intestinal dysfunction in ASD showed
increased monocytes, lymphocytes, NK cells, eosinophils,
and intraepithelial lymphocytes in duodenal biopsies, and
autoantibody IgG and co-localized C1q complement bound
to the basal membrane of GI epithelial cells (Torrente et al.,
2002). This autoimmune phenomena—directed against the gut
lumen barrier—could be responsible for the increased intestinal
permeability seen in individuals with ASD (de Magistris et al.,
2010). Inflammatory immune cells were found to infiltrate the
epithelium and lamina propria of the GI tract (Furlano et al.,
2001; Torrente et al., 2002; Ashwood et al., 2003). Further,
studies showing increased production of inflammatory cytokines
and decreased regulatory IL-10 production by mucosal Cluster
of Differentiation(CD)3+ T cells suggested the presence of
increased inflammation and dysregulation of mucosal immune
responses that could be contributing to disruption of the
intestinal barrier (Ashwood et al., 2004; Ashwood andWakefield,
2006). Mucosal gene profiling adds further support to these
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findings, with upregulation of cytokine production, including IL-
17 and increased immune activation in children with ASD who
have comorbid GI issues (Walker et al., 2013).
Increased inflammation and dysregulation of the GI tract in
ASD is important as this compartment comprises a significant
percentage of immune cells in the body, and immune cells
educated here participate in immune function throughout the
body. Cellular education and the maintenance of regulatory
immune cells in the mucosal GI compartment are strongly
influenced by the community of microbes that reside here, and
this influences systemic immune homeostasis (reviewed in Wu
andWu, 2012). Additionally, if the intestinal barrier is disrupted,
antigenic material from the lumen of the gut may enter the
periphery and initiate an immune response. Indeed, ASD subjects
with GI comorbidities have increased peripheral inflammation
and lower production of regulatory cytokines (Jyonouchi et al.,
2001, 2005, 2011; Ashwood and Wakefield, 2006; Rose et al.,
2018). Circulating antigens and bacterial metabolites could also
directly influence the brain if both the intestinal and blood-
brain barriers are not sufficiently intact. This is one proposed
mechanism of how the microbiota-gut-brain axis may have
pathological involvement in neurological disorders (Cryan and
Dinan, 2012). Interestingly, recent findings in post-mortem
tissue suggest that individuals with ASD have alterations in
the blood-brain barrier and deficiencies in gene expression of
intestinal tight junction proteins (Figure 2) (Fiorentino et al.,
2016). Several studies have also indicated that individuals with
ASD have dysbiotic alterations in gut flora and altered bacterial
metabolites (Figure 2) (Finegold et al., 2010; Williams et al.,
2011, 2012; Gondalia et al., 2012; Kang et al., 2013; Tomova
et al., 2015; Strati et al., 2017; Hughes et al., 2018), including
recent findings that children with ASD who exhibit GI symptoms
have differences in microbiota compared to children with ASD
who have no GI dysfunction. Their microbiota also differed
from typically developing children with similar GI symptoms
(Rose et al., 2018). These studies suggest an ineffective immune
response to bacteria in ASD, or production of inflammatory
mediators leading to preferential bacterial growth (Spees et al.,
2013). It is unclear whether the dysbiosis seen in ASD is driving
the immune dysfunction and altered immune regulation, or is a
result of it and much more research is needed in this area.
It has been suggested that food allergy may play a role in GI
dysfunction, and some parents of children with ASD have seen
behavioral improvements after implementing diets that eliminate
suspect antigens such as gluten and casein; however, the role
of food allergies remains controversial. Reports of IgE-mediated
food allergies correlating with GI symptoms are inconclusive
(Buie et al., 2010), although, one group found a high incidence
of non-IgE-mediated food allergy in younger children with ASD
(Jyonouchi et al., 2008). Celiac disease has also been reported to
have an association with ASD (Barcia et al., 2008; Ludvigsson
et al., 2013). A recent Italian study looked at a cohort of 382
preschoolers diagnosed with ASD, and found the prevalence of
celiac disease among the ASD cohort was significantly increased
compared to the general pediatric population, with an overall
prevalence of 2.62% (Calderoni et al., 2016). This supports the
earlier work by Barcia et al. who found a 3.3% prevalence of celiac
disease in ASD by exploring biopsied tissue (Barcia et al., 2008).
As GI disturbances may exacerbate behavioral symptoms, better
screening techniques that include identification of behaviors
associated with GI distress may help to better elucidate the actual
prevalence within this population.
Additional research seeking to identify a genetic and
molecular basis for the comorbidities plaguing individuals
with ASD consistently found dysregulation of multiple innate
signaling pathways by utilizing searches of curated gene
pathways. Nine Kyoto Encyclopedia of Genes (KEGG) pathways
were recently identified to overlap in ASD and other disease
comorbidities common in ASD. For example, three pathways
involved in regulation of the immune response, the toll-
like receptor (TLR), nucleotide-binding and oligomerization
domain (NOD) pathways, and chemokine signaling pathways
significantly overlapped with asthma and inflammatory bowel
disease (Nazeen et al., 2016). Further studies are needed to
examine these pathways in ASD. However, it is important to
note that not all of these dysregulated pathways may exist
in individuals with ASD (Campbell et al., 2013), but may be
dysregulated in those with immune comorbidities and help
account for the wide heterogeneity and conflicting results seen
in some studies in ASD.
Autoantibodies in Individuals With ASD
In addition to antibodies targeting the GI epithelium,
autoantibodies specific to self-proteins in the brain, CNS
and cellular components have been frequently reported in
individuals with ASD (Figure 2, Table 4). Autoantibodies are a
common feature in autoimmunity, and their presence may be
predictive of the development of certain autoimmune disorders
(Anaya et al., 2007; Lleo et al., 2010). Presence of autoantibodies
that react to components of the brain and CNS in individuals
with ASD have been identified since as early as 1988, when
antibodies to neuron-axon filament proteins (NAFP) were found
in 10 out of 15 children with ASD (Singh et al., 1988). A year
later, researchers identified IgG and IgM antibodies that target
cerebellar neurofilaments (Plioplys et al., 1989). Anti-myelin
basic protein (MBP) antibodies were identified in individuals
with ASD in 1993 (Singh et al., 1993) and later supported by
additional studies (Singh et al., 1998; Connolly et al., 2006).
The anti-MBP results have been replicated in additional studies,
including a 2013 investigation that linked these autoantibodies to
both severity of ASD as well as allergic manifestations (Mostafa
and Al-Ayadhi, 2013). However, other studies have refuted
these findings which underscores the wide variations of immune
phenotypes seen in ASD (Libbey et al., 2008).
More recent studies have found autoantibodies to the
prefrontal cortex, caudate, putamen, cerebellum and cingulate
gyrus regions of the brain (Singer et al., 2006) and hypothalamus
(Cabanlit et al., 2007) in children with ASD. In 2009, researchers
found that 21% of plasma samples from children with ASD
had intense immunoreactivity to Golgi neurons in primate
cerebellum, with no reactivity occurring in controls. These ASD
autoantibodies reacted to a protein of a molecular weight of
52kDa in human cerebellum (Wills et al., 2009). A follow-
up study identified reactivity to interneurons in other regions
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TABLE 4 | Studies identifying presence of autoantibodies in individuals with ASD.
Subject details Methods Summarized findings References
48 autism (5.9 ± 3.9 years)
19 CDD (7.0 ± 2.4 years)
14 PDD-NOS (4.8 ± 3.9
years)
9 LKS (7.4 ± 2.3 years)
37 epilepsy (5.9 ± 3.8 years)
29 HC (4.3 ± 2.0 years)
21 NNI (4.2 ± 2.6 years)
Serum ELISA measurements of BDNF, IgG/IgM auto-Abs
to BDNF, endothelial cells, MBP, and histones
Note: Subject numbers indicate total included in study.
Actual numbers varied slightly depending on assay
↑ BDNF in ASD, CDD compared to HC and NNI
↑ anti-BDNF IgM and IgG in autism, CDD and
epilepsy compared to HC
↑ IgM to endothelial cells in autism, CDD,
PDD-NOS, and epilepsy compared to HC and NNI
↑ IgG to endothelial cells in autism and PDD-NOS
compared to HC
↑ IgM and IgG to MBP in autism, CDD, PDD-NOS,
and epilepsy compared to both HC and NNI, LKS
not elevated
Connolly et al., 2006
29 ASD (3–12 years)
9 SIB (4–8 years)
13 TD (9–17 years)
Serum ELISA and Western blot reactivity to human brain ↑ reactivity to 100 kDa epitope in caudate putamen
and prefrontal cortex in ASD
↑reactivity to 73 kDa epitope in cerebellum and
cingulate gyrus in ASD and SIB
Singer et al., 2006
63 ASD (2–15 years)
63 TD (2–14 years)
25 SIB (1–13 years)
21 DD (2–5 years)
Western blot of plasma reactivity to adult human
hypothalamus and thalamus protein extracts
↑ reactivity to 52 kDA thalamus and hypothalamus
proteins in ASD
↑ reactivity to 3 hypothalamus proteins (42–48 kDa
MW)
Cabanlit et al., 2007
11 ASD
9 SIB
(>6 years)
72-h neuronal culture analyzed for effect of ASD sera on
differentiation of NPCs by immunoblotting, morphometry,
and immunocytochemistry
Treatment with ASD sera:
↓ NPC proliferation
↑ cell migration
↑small cells with processes
↑ length and number of processes
↑ synaptogenesis
Mazur-Kolecka et al.,
2007
33 ASD (7.3 ± 3.0 years)
26 regressive autism (6.7 ±
2.7 years)
25 TD (8.9 ± 3.4 years)
24 Tourette syndrome (10.0
± 2.6 years)
Plasma ELISA and Western blot reactivity to MBP ↑ auto-Abs to MBP found in regressive autism
compared to classic (infantile) autism and Tourette
syndrome subjects.
Libbey et al., 2008
63 ASD (2–15 years)
63 TD (2–14 years)
25 SIB (1–13 years)
21 DD (2–5 years)
Western blot of plasma reactivity to human cerebellar
protein extracts. Cerebellar-specific auto-Abs detected
by IHC of Macaca fascicularis monkey cerebellum.
↑auto-Abs to 52 kDa cerebellar protein in ASD
↑“intense immunoreactivity” to Golgi cells of the
cerebellum in ASD, associated with auto-Abs to 52
kDa cerebellar protein
Wills et al., 2009
37 ASD (1–12 years)
37 TD (1–14 years)
Measured effect of ASD sera on cell response to
oxidative stress via immunoblotting, morphology,
immunofluorescence, apoptosis, and proliferation
assays.
Oxidative stress reduced proliferation in
differentiating NPCs treated with TD sera. Effect
was not as prominent with ASD sera, indicating an
altered response to oxidative stress.
Mazur-Kolecka et al.,
2009
20 ASD (3.0 ± 0.4 years)
12 TD (3.0 ± 1.2 years)
Taqman Real time PCR to detect serum mtDNA. Serum
ELISA analysis to detect mtDNA antibodies
↑ extracellular mtDNA in ASD
↑ anti-mtDNA auto-Abs (type 2) in ASD
Zhang et al., 2010
277 ASD (70 BAP)
189 TD
(2–5 years)
Western blot for child plasma reactivity to Rhesus
macaque cerebellum protein medley
↑auto-Abs to 45 kDa protein in ASD
↑auto-Abs to 62 kDa protein in BAP
Increases in either auto-Ab was associated with
lower adaptive and cognitive scores, increased
aberrant behaviors.
Goines P. et al., 2011
54 ASD
54 TD
(4–11 years)
Serum anti-ganglioside M1 Abs were measured by ELISA ↑ antiganglioside M1 auto-Abs in ASD, especially in
severe compared to mild or moderate autism.
Mostafa and Al-Ayadhi,
2011
86 ASD (2.0–5.6 years)
43 TD (2.3–4.7 years)
IHC for plasma reactivity to sections of macaque monkey
brain (methods similar to Wills et al., 2009), results
compared to behavioral assessments.
No differences in rate of plasma immunoreactivity to
cerebellar Golgi neurons and other neural elements
in ASD vs. TD, however immunoreactivity
associated with worsening behavior and higher
multiple CBCL scores.
Rossi et al., 2011
(Continued)
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TABLE 4 | Continued
Subject details Methods Summarized findings References
7 ASD with reactivity (2.5 to
7 years)
7 ASD with no reactivity
6 TD with no reactivity (2.5
to 8 years)
IHC: follow up of subgroup of ASD children from
previous study (Wills et al., 2009) with reactivity to
cerebellar 52-kDa protein and to Golgi cell region of the
cerebellum. IHC to detect plasma immunoreactivity in
the maqaque and male mouse brains.
Reactivity seen in previous study identified as
GABAergic interneurons (based on co-localization
of staining to calcium-binding proteins).
Reactivity extended to other regions of the brain
with slight preponderance to superficial layers of the
cortex.
Wills et al., 2011
80 ASD
80 TD
(6–12 years)
Indirect immunofluorescence used to measure serum
anti-neuronal antibodies
↑ anti-neuronal auto-Abs in ASD, associated with
increased severity of autism and seen more
frequently in females ASD (90 vs. 53.3%, P =
0.001).
Mostafa and Al-Ayadhi,
2012b
50 ASD
30 TD
(5–12 years)
Serum ELISA measurements of 25-hydroxy vitamin D
and anti-MAG autoAbs
↓ 25-hydroxy vitamin D in ASD
↑ anti-MAG auto-Abs in ASD
25-hydroxy vitamin D levels negatively correlated
with CARS scores and anti-MAG auto-Abs
Mostafa and Al-Ayadhi,
2012a
54 ASD
22 DD
33 TD
(2–5 years)
Plasma ELISA measurements of anti-cardiolipin,
anti-phosphoserine, and anti-β-glycoprotein 1 auto-Abs
↑ auto-Abs to cardiolipin, phosphoserine, and
β-glycoprotein 1 in ASD compared to TD and DD
controls, significantly associated with worsening
behaviors.
Careaga et al., 2013
42 ASD
42 TD
(6–11 years)
Serum ELISA measurement of human anti-MBP Abs.
Severity of ASD and manifestation of allergic/asthma
symptoms compared to results.
↑ auto-Abs to MBP and MAG in ASD, regardless of
allergies.
Severity of autism was also found to be associated
with increased allergies.
Mostafa and Al-Ayadhi,
2013
93 ASD
(2.9–17.4 years)
Patented process of identifying FRA: incubated serum
with folate receptors then added radio-labeled folic acid.
HPLC measurement of 5-MTHF in the CSF.
↑ prevalence of FRA in ASD sera.
Blocking FRA correlated with CSF 5-MTHF
concentrations in 16 children.
Treatment with folinic acid improved attention,
language and communication, and repetitive
behaviors, with “moderate to much” improvement
seen in 1/3 of children treated.
Frye et al., 2013
75 ASD (2–22 years)
30 DD (1–18 years)
Patented process of identifying FRA: incubated serum
with folate receptors then added radio-labeled folic acid.
↑ prevalence of FRA in ASD vs. DD
↑ prevalence of FRA in parents of ASD vs. DD,
suggesting familial autoimmune component to ASD
Ramaekers et al., 2013
20 ASD (1.4–5 years)
18 TD (1.4–4.4 years)
Immunoblotting and immunocytochemistry to detect
serum auto-Abs against differentiating NPCs
↑ auto-Abs against human neuronal progenitor cell
proteins of 55, 105, 150, and 210 kDa molecular
weights in ASD subjects compared to controls.
Strongest reactivity noted in NPCs expressing Tuj1.
Mazur-Kolecka et al.,
2014
100 ASD
100 TD
(4–11 years)
ELISA measurement of serum anti-ds-DNA Abs.
Immunofluorescence measurement of serum antinuclear
Abs.
↑ anti-ds-DNA and anti-nuclear auto-Abs in ASD
Presence of anti-ds-DNA auto-Abs positively
associated with a family history of autoimmunity.
Mostafa et al., 2014
355 ASD
142 SIB
(2–47 years, mean age:
9.06)
Western blot plasma reactivity to homogenized Rhesus
macaque brain tissue and human adult cerebellum
Plasma reactivity at 45 and 62 kDa brain proteins
associated with autism severity and larger head
circumference. 45 kDa reactivity associated with
cognitive impairment/lower VABS scores while 62
kDa reactivity associated with stereotypies.
Piras et al., 2014
60 ASD
60 TD
(3–12 years)
ELISA measurement of serum anti-nucleosome-specific
antibodies.
↑ anti-nucleosome-specific auto-Abs in ASD,
associated with family history of autoimmunity.
Al-Ayadhi and Mostafa,
2014
55 ASD (3–12 years)
25 TD (4–12 years)
ELISA measurement of plasma levels of anti-endothelial
cell antibodies
↑anti-endothelial cell auto-Abs in children with
autism compared to healthy controls, associated
with autism severity.
Bashir and Al-Ayadhi,
2015
(Continued)
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TABLE 4 | Continued
Subject details Methods Summarized findings References
62 ASD (4–11 years)
62 TD (5–12 years)
ELISA measurement of serum ENA-78 and anti-neuronal
auto-antibodies
↑ anti-neuronal auto-Abs in ASD
↑ENA-78 (neutrophil-recruiting chemokine CXCL5)
associated with increases in anti-neuronal auto-Abs
Mostafa and Al-Ayadhi,
2015
40 ASD/FRAA-(7.0 ± 3.3
years)
16 ASD/FRAA blocking +
(6.4 ± 3.0 years)
48 ASD/FRAA binding +
(7.3 ± 3.1 years)
Measured redox, methylation, vitamins and immune
biomarkers using various assays and compared to
behavioral assessments
↓ 3-Chlorotyrosine (a marker of inflammation) was in
those positive for blocking FRAs
Presence of blocking FRAs in ASD associated with
less severe ASD symptoms compared to ASD
negative for these FRAs
Frye et al., 2016
ASD, autism spectrum disorders; CDD, childhood disintegrative disorder with regression after age 2 years; PDD-NOS, pervasive developmental disorder-not otherwise specified; LKS,
Landau-Kleffner syndrome; HC, healthy children; NNI, children with non-neurologic illnesses; ELISA, enzyme-linked immunosorbent assay; BDNF, brain-derived neurotrophic factor;
MBP, myelin basic protein; SIB, typically-developing sibling; TD, typically developing child; kDa, kilodalton; DD, non-ASD developmentally delayed; NPCs, human neuronal progenitor
cells; MEF, myelin-enriched fraction of the brain; AEF, axolemma-enriched fraction of the brain; IHC, immunohistochemistry; auto-Abs, autoantibodies; PCR, polymerase chain reaction;
mtDNA, mitochondrial DNA; BAP, broader diagnosis of autism spectrum disorder; CBCL, The Child Behavior Checklist; MAG, myelin-associated glycoprotein; FRA, folate receptor
antibodies; 5-MTHF, 5-methyltetrahydrofolate; CSF, cerebrospinal fluid; Tuj1, neuron-specific Class III β-tubulin; ds-DNA, double-stranded DNA; VABS, Vineland Adaptive Behavior
Scales; ENA-78, Epithelial cell-derived neutrophil-activating peptide-78; CXCL5, C-X-C motif chemokine 5.
of the brain, including those in the superficial layers of
the cortex. The target neurons were identified as specifically
GABAergic. GABAergic Golgi neurons and interneurons are
inhibitory, utilizing the neurotransmitter gamma-aminobutyric
acid (GABA) to modulate nearby excitatory synapses. It is
unknown whether these antibodies are able to cross the blood-
brain barrier (Wills et al., 2011). However, if they are able to enter
the brain and reach their target antigens, this could potentially
alter numbers or activity of inhibitory neurons, and contribute to
the imbalance in excitatory/inhibitory activity that has long been
suggested to contribute to certain aspects of ASD (Rubenstein
and Merzenich, 2003).
Eighty-six children with ASD and forty-three typically
developing controls from the Autism Phenome Project, a large
multidisciplinary study conducted at the MIND Institute, were
further assessed for these neuronal autoantibodies. Similar
reactivity to cerebellar Golgi neurons and interneurons was
found throughout the brain in some children with ASD;
however, the results were not significantly different than
controls, and in contrast to (Wills et al., 2009), some typically
developing children also exhibited positive staining. Although
these results did not support previous findings that these
autoantibodies occur solely in ASD, this group did find a
correlation between immunoreactivity and increased scores on
the Child Behavior Checklist (CBCL), indicating worsening
behaviors with immunoreactivity (Rossi et al., 2011). This
finding that the autoantibodies are also present in typically
developing children suggests that in ASD, there may be some
other pathological mechanism that is allowing the autoantibodies
to enter the typically “immune-privileged” brain, contributing
to ASD behaviors (Rossi et al., 2011). Using human protein
extracts as antigenic targets the same researchers found antibody
reactivity to CNS proteins at two separate molecular weights (45
and 62 kDa) that correlated with worsening behaviors in children
with ASD (Goines P. et al., 2011). Autoantibodies specific for
a 45 kDa cerebellar protein were associated with a diagnosis of
autism disorder (Goines P. et al., 2011) and cognitive impairment
(Piras et al., 2014), while autoantibodies directed toward the
62 kDa protein were associated with the broader diagnosis of
ASD (Goines P. et al., 2011) and motor stereotypies (Piras
et al., 2014). A Saudi Arabian cohort of children with ASD
also showed high levels of autoantibody reactivity to cerebellar
neurons, the presence of which was positively associated with
ASD severity (Mostafa and Al-Ayadhi, 2012b). Increased serum
autoantibodies against human neuronal progenitor cell (NPC)
proteins of 55, 105, 150 and 210 kDa molecular weights in ASD
have also been identified, with the strongest reactivity noted
in neuronal progenitor cells expressing the mature neuronal
marker Tuj1, as opposed to astrocytes expressing Glial fibrillary
acidic protein (GFAP) (Mazur-Kolecka et al., 2014). This group
had previously found that sera from ASD subjects suppressed
differentiation and maturation of NPCs in culture and provided
a potential mechanism for aberrant neurodevelopment in ASD
(Mazur-Kolecka et al., 2007, 2009, 2014).
Serum antibodies to ganglioside M1, the most abundant
sialylated glycosphingolipid component of neuronal membranes,
were found to be significantly higher in children with
ASD compared to controls, with highest levels seen in the
most severe cases of ASD (Mostafa and Al-Ayadhi, 2011).
Serum autoantibodies to gangliosides are frequently seen in
autoimmune disorders associated with neurological impairment,
such as SLE and Guillain-Barré syndrome (Mostafa et al., 2010b;
Kusunoki and Kaida, 2011). Additional autoantibodies identified
in individuals with ASD include those reactive to cardiolipin,
phosphoserine, and β2-glycoprotein 1 (Careaga et al., 2013),
endothelial cells (Zhang et al., 2010; Bashir and Al-Ayadhi,
2015), myelin-associated glycoprotein (Mostafa and Al-Ayadhi,
2012a, 2013), double stranded DNA, nucleus and nucleosomes
(Al-Ayadhi and Mostafa, 2014; Mostafa et al., 2014) and
mitochondrial DNA (Zhang et al., 2010). Recently, folate receptor
autoantibodies (FRA) have come to the forefront of autoantibody
studies in children with ASD. In 2013, Frye et al. found FRAs
to be prevalent in children with ASD (75%), including blocking
and binding FRAs, with 29% being positive for both FRAs (Frye
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et al., 2013). This study additionally looked at supplementation
of folinic acid, as FRA may be interfering with folate transport
across the blood-brain barrier, and found improvement in
communication, language, attention and stereotypic behaviors in
treated children compared with non-supplemented ASD controls
(Frye et al., 2013). In support of these findings, a Belgium study
found significantly higher prevalence of blocking FRA in ASD
compared to non-autistic individuals with developmental delays
(Ramaekers et al., 2013). Both studies also found a statistically
significant increase in FRAs among the parents of individuals
with ASD, suggesting a relationship with familial autoimmunity.
However, not all parents harbored these autoantibodies, and this
suggests that in some instances there is postnatal acquisition of
FRA (Frye et al., 2013; Ramaekers et al., 2013). 3-Chlorotyrosine,
a marker of myeloperoxidase protein damage and inflammation,
was significantly lower in those positive for blocking FRAs,
suggesting that this group may have less inflammation than their
counterparts positive for binding FRAs. Moreover, the presence
of blocking FRAs in children with ASD was associated with less
severe ASD symptoms compared to those who were negative for
blocking FRA (Frye et al., 2016). Further studies characterizing
immune activation in the different FRA groups could help clarify
this relationship.
It is important to note that although the presence of
autoantibodies are commonly found in autoimmunity, they
may not be specific to any single disorder and can be present
to some degree in healthy individuals, therefore they are
not diagnostic without direct or indirect evidence (Rose and
Bona, 1993; Lacroix-Desmazes et al., 1998). It is currently
unknownwhether these autoantibodies found in individuals with
ASD play a causal role in the etiology of the disorder. The
lack of consistency in target antigens and wide heterogeneity
of type and presence of these autoantibodies suggest they
may in fact be epiphenomenon in at least some cases of
ASD due to general immune dysregulation (Wills et al.,
2009). Collateral damage can occur from unregulated or
excessive inflammatory responses, causing subsequent epitope
spreading which leads to the development of autoantibodies
characteristically seen in autoimmunity (Vanderlugt and Miller,
1996).
Aberrant Innate Immune Responses
Neuroinflammation
One of the major advancements in ASD research in the last 10
years is evidence that active neuroinflammation is a significant
component of ASD, including chronically activated microglia
(Figure 2). Findings of increased microglial and astroglial
activation in the cerebellum and various regions of the cortices,
specifically increased HLA-DR and GFAP via immunostaining
(Vargas et al., 2005) has prompted additional research in this
area. These early findings included increases in proinflammatory
cytokines in the CSF and within several regions of the brain such
as macrophage chemoattractant protein (MCP)−1, a cytokine
important for monocyte recruitment. Findings also included
marked increases in CD68+ perivascular macrophages and
monocytes, suggesting the possibility of monocyte infiltration,
which is one of the markers considered when autoimmunity
is suspected in MS and EAE models (van Der Valk and De
Groot, 2000; Vogel et al., 2013). Additionally, a significant
loss of Purkinje neurons in the cerebellum was noted in
ASD subjects compared with controls, and anti-inflammatory
cytokines were associated with degenerative Purkinje cells
and cerebellar astroglia, suggesting an attempt to modulate
inflammation in the presence of damaged tissue (Vargas et al.,
2005).
Microglia were later characterized in post-mortem brain
samples of ASD subjects, revealing alterations indicative of
an activated microglia phenotype including increased somal
volume, increased density, and amoeboid presentation in 9
of 13 ASD cases (Morgan et al., 2010). These alterations
were not correlated with age and researchers found no co-
localization of Interleukin 1 receptor, type I (IL-1R1) with the
monocyte/microglia marker ionized calcium binding adapter
molecule 1 (Iba-1). IL-1R1 is upregulated rapidly during acute
inflammation, therefore this lack of increased co-localization
suggests this is not an acute inflammatory event, rather a long-
standing alteration in the brains of ASD subjects (Morgan et al.,
2010). This group later found increases in spatial clustering of
microglia to neurons in these brain samples, suggesting neuron-
directed recruitment of microglia in ASD subjects (Morgan et al.,
2012). Considered the resident innate immune cells of the brain,
microglia colonize the brain during the early embryonic period
and are essential to neurodevelopment, including involvement
in angiogenesis (Fantin et al., 2010; Rymo et al., 2011),
regulation of astrocytic differentiation from neuronal precursor
cells (Nakanishi et al., 2007), synaptic pruning (Paolicelli et al.,
2011) and clearance of newborn neuronal precursors destined for
apoptosis (Sierra et al., 2010).When activated to an inflammatory
phenotype, microglia secrete inflammatory cytokines including
tumor necrosis factor-alpha (TNF-α), IL-1β and IL-6 and
produce nitric oxide synthase (iNOS) (Reviewed in Smith
et al., 2012). Although some microglia activation is required
for productive neurodevelopment (Cunningham et al., 2013),
chronic activation is associated with disease states (Smith et al.,
2012). Furthermore, excessive activation can lead to cell death
and abnormal or reduced connectivity (Rodriguez and Kern,
2011).
To gain a more specific picture of the pro-inflammatory
cytokine milieu in the brains of ASD subjects, Li et al. (2009)
further investigated cytokines associated with inflammatory
responses in post-mortem tissue and found significantly
increased pro-inflammatory cytokines including interferon
gamma (IFNγ) associated with NK cells and T helper (TH)-
1 activation (Li et al., 2009). In support of altered immune
regulation and function in the brains of ASD subjects, recent
transcriptome analyses of the superior temporal gyrus and
cerebral cortex of postmortem samples indicated upregulation
of genes involved in immunity and inflammation, including
markers of activated microglia and pathways of innate immunity
(Garbett et al., 2008; Voineagu et al., 2011) More recent
transcriptome analyses of multiple cortical areas of ASD
brains support and add to these findings. Large scale RNA
sequencing revealed that the dysregulated co-expression module
found in the brains of ASD subjects by Voigneau et al. was
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enriched for activation specific to the microglia, and showed
increased expression of “immune-response” genes (Gupta et al.,
2014). Correlating well with these findings, methylation studies
have identified that immune-response genes in frontal cortex
of individuals with ASD have hypomethylated CpG sites,
causing increased transcription of inflammatory genes such
as TNF-α, integrin and complement genes, and genes that
encode transcription factors involved in microglial development
(Nardone et al., 2014).
To allow for in-vivo study of individuals with ASD, Suzuki and
colleagues utilized positron emission tomography (PET) analysis
to assess binding values of the [11C](R)-PK11195 radiotracer
that binds selectively to the mitochondrial 18 kDa translocator
protein (TSPO), specifically targeting activated microglia. They
found significantly increased binding values in several regions of
the brain compared to controls, suggesting increased microglia
activation in all regions analyzed compared to controls, including
the cerebellum, several regions of the cortex, and the corpus
callosum (Suzuki et al., 2013). These in-vivo findings support
studies of increased microglia activation in post-mortem tissue;
however, it is important to note that (1) the sample sizes
were small and only included individuals with high-functioning
ASD, (2) significant non-specific binding can occur with the
[11C](R)-PK11195 radiotracer, and (3) researchers were unable to
normalize binding values due to lack of a microglia-free reference
region (Suzuki et al., 2013). These findings warrant additional in-
vivo studies with larger sample sizes/additional ASD phenotypes,
and ideally a more-specifically binding radiotracer.
Peripheral Innate Immune Dysfunction
Aberrant innate immune responses are not restricted to
the brain and CNS in individuals with ASD, alterations in
circulating monocytes, dendritic cells and NK cells have also
been identified (Figure 2). Early studies found an increased
number of monocytes in the peripheral blood of children with
ASD (Denney et al., 1996; Sweeten et al., 2003b), and elevated
production of IFNγ, IL-1RA, and a trend for elevated IL-
6 and TNF-α in whole blood cultures, suggesting increased
activation ofmonocytes in individuals with ASD (Croonenberghs
et al., 2002a). In support of these findings, a recent study
found increased CD95, a marker of activation on monocytes
in the peripheral blood of children with ASD (Ashwood
et al., 2011a). Sweeten and colleagues also found elevated
plasma neopterin, a pyrazinopyrimidine compound produced by
monocytes and macrophages in response to IFNγ stimulation,
indicating increased cellular immune activation (Murr et al.,
2002; Sweeten et al., 2003b). Additionally, after TLR2 and TLR4
stimulation, upregulation of inflammatory cytokines and the
HLA-DR activation marker was seen in monocytes from children
with ASD versus typically developing children (Enstrom et al.,
2010). Dendritic cell numbers were also increased in children
with ASD and associated with bigger amygdala size and more
aberrant behaviors (Breece et al., 2013).
An early study investigating induced responses of immune
cells in children with ASD found increased production of the
innate cytokines: TNF-α, IL-1β, and IL-6 after stimulation of
peripheral blood mononuclear cells (PBMC) with the TLR-
4 ligand lipopolysaccharide (LPS), from children with ASD
when compared to typically developing children (Jyonouchi
et al., 2001). To improve understanding of differential innate
responses to varied TLR stimuli in ASD, investigators measured
innate responses to several environmentally relevant pathogen-
associated molecular patterns (PAMPs). The outcome of this
study demonstrated elevated cytokine production after exposure
to several innate immune ligands. Stimulation of isolated
monocytes with TLR2 ligand lipoteichoic acid (LTA) produced
a significant increase in production of TNF-α, IL-1β, and IL-
6 in children with ASD versus typically developing controls,
supporting earlier works. TLR4 stimulation with LPS also
produced increased IL-1β. Moreover, increased production of
IL-1β after LPS stimulation was found to be associated with
worsening behaviors (Enstrom et al., 2010). Recently, Nadeem
et al. identified increases in the IL-17RA receptor on circulating
monocytes in children with ASD (Nadeem et al., 2018). IL-
17RA is the receptor for IL-17A, a cytokine associated with
autoimmunity and implicated in rodent models of ASD (Choi
et al., 2016). Increased expression of the nuclear transcription
factor NFkB and inducible nitric oxide synthase (iNOS) were
also noted in ASD groups. Cells treated with IL-17 increased
expression of iNOS/NFkB and blockade of IL-17 reversed this
inflammatory profile (Nadeem et al., 2018). These data may
suggest a link between adaptive arm of the immune system and
innate immune dysfunction in people with ASD.
Significant increases in cytokines associated with innate
inflammation have also been found in phytohemagglutinin
(PHA) stimulated PBMC of children with ASD, including TNF-
α and GM-CSF (Ashwood et al., 2011b). Excessive production
of pro-inflammatory cytokines initiated by the innate immune
system could have downstream consequences including over-
activation of the adaptive arm, leading to autoimmune sequelae.
Abnormal innate cytokines have also been identified in the
plasma and sera of individuals with ASD. Significant increases
in plasma levels of IL-1β, IL-6, and TNF-α suggest increased
activation of the innate arm (Emanuele et al., 2010; Ashwood
et al., 2011b; Suzuki et al., 2011; Ricci et al., 2013) and
are consistent with the dynamic responses seen previously
in stimulated monocytes (Enstrom et al., 2010; Ashwood
et al., 2011c). Other innate-associated cytokines reported to
be elevated in the plasma or sera of individuals with ASD
when compared to typically developing controls include IL-
12p40 and the chemokines IL-8, MCP-1, regulated on activation,
normal T cell expressed and secreted (RANTES), eotaxin and
C-X-C motif chemokine 5 (CXCL5) (Ashwood et al., 2011b;
Suzuki et al., 2011; Mostafa and Al-Ayadhi, 2015). While there
have been a few contradictory reports regarded plasma/sera
cytokine concentrations individuals with ASD, a recent meta-
analysis of plasma cytokines showed significant evidence of
abnormal cytokine/chemokine profiles in individuals with ASD
versus healthy controls, including elevated IL-1β, IL-6, IL-
8, IFN-γ, and MCP-1, and reduced concentrations of the
anti-inflammatory cytokine transforming growth factor beta 1
(TGFβ1) (Masi et al., 2015). Further characterization of ASD
subjects found that circulating plasma levels of pro-inflammatory
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cytokines associated with increased innate immune activation
correlated with worsening behaviors, which suggests that
ongoing inflammation likely contributes to the severity of
behaviors (Ashwood et al., 2011b). Leukocyte adhesionmolecules
have also been investigated in children with ASD, and were found
to be reduced, indicating dysfunctional immune-endothelial cell
interactions that could have implications for the migration of
innate immune cells into the CNS (Onore et al., 2012).
NK cells are important early responders of the innate immune
system. They specifically target virally infected cells and play
important roles in both tumor surveillance and protection of
the fetus during pregnancy. As early responders, they can
initiate a cascade of immune responses and if dysfunctional
these important signals may be missing or altered (Mandal and
Viswanathan, 2015). A significant increase of total numbers
of NK cells, identified as CD56+CD3−, was observed in
children with autism with both high and low IQ (Ashwood
et al., 2011a). Cytokines produced by NK cells expressing
high levels of CD56 can significantly influence the cytokine
milieu. Upregulation of mRNA responsible for expression of
receptors including killer-cell immunoglobulin-like receptors
[KIRs] and increased cytokine, perforin, and granzyme B
production was observed at resting levels in NK cells from
2 to 5 year old children with ASD (Enstrom A. M. et al.,
2009). The cytolytic function of NK cells is important for
immune regulation, as they can remove persistently activated
immune cells (Cook et al., 2014). Interestingly, when stimulated,
significantly decreased cytotoxicity and lower production of
effector molecules (granzyme, perforin, and IFNγ) were seen
in children with ASD compared to controls (Enstrom A. M.
et al., 2009). Decreased cytolytic activity was seen previously
in a large subgroup of children with ASD (Vojdani et al.,
2008). This pattern suggested that NK cell activation may be
“maxed-out” in vivo, and the cells may be unable to respond to
further stimuli. Similar patterns of increased CD56+ NK cells
but impaired cytolytic activity have been seen in the peripheral
blood of patients with autoimmune disorders such as MS,
T1DM, SLE, and RA (Fogel et al., 2013), again adding evidence
of an autoimmune component/lack of immune regulation in
individuals with ASD.
Aberrant Adaptive Immune Responses
T Cells
Over the last 10 years, researchers have found significant
abnormalities of the adaptive arm of the immune system in
people with ASD, including altered numbers of lymphocytes,
dysregulation of T and B cell activation, and altered adaptive
cytokine production (Figure 2). Increased total numbers of T
cells and skewed ratios of CD4 to CD8 lymphocytes have been
associated with decreased executive function in people with
ASD (Han et al., 2011). Several studies have also shown altered
cytokine production in T cells. Molloy et al. found a shift to a
TH2 phenotype with significant increases in IL-4, IL-5, and IL-13
after stimulation in vitro (Molloy et al., 2006b). Altered surface
markers of T cell activation have also been seen. Specifically, the
T cell activation markers HLA-DR and CD26 were found to be
increased in children with ASD (Ashwood et al., 2011a). CD5,
a transmembrane protein associated with T cells and found to
be elevated in autoimmunity (Sigal, 2012), was recently found
to be significantly elevated in plasma of ASD subjects, and is
associated with worsening severity of ASD (Halepoto et al., 2017).
In response to stimulation, T cells from children with ASD also
showed increased CD134 and increased cellular proliferation
associated with worsening behaviors (Ashwood et al., 2011b).
CD134 (also known as OX40) is a co-stimulatory molecule
expressed on activated T cells, including memory T cell subsets
(Webb et al., 2016) that is required for optimal activation of naïve
T cells and is important in survival and maintenance of memory
T cells.
Significant alterations in cytokines associated with the
adaptive arm have been found in children with ASD versus
controls, including IL-5, IL-13, IL-17 (Suzuki et al., 2011), IL-
23 and IL-12 (Ricci et al., 2013), IL-21 and IL-22 (Ahmad et al.,
2017a). Two recent studies found altered cytokine profiles in
neonatal blood spots, suggesting early immune dysregulation.
Increased IL-4 at birth was associated with increasing severity
of ASD, and increased IL-1β with milder versions of ASD
(Krakowiak et al., 2017). Zerbo et al. observed increased MCP-
1 and decreased RANTES at birth in children with ASD (Zerbo
et al., 2014). It is noteworthy to mention that various reports of
T cell skewing in ASD does not necessarily implicate a specific
polarization associated with the disorder, rather it supports the
suggestion that a lack of regulation may be at play. A recent
study clustered subjects into immune endophenotypes based on
T cell polarization after stimulation with PHA, and found that
both TH1 and TH2 responses were associated with worsening
behaviors and increased severity of core ASD symptoms (Careaga
et al., 2017). Transcription factors associated with inflammatory
T cell activation, and different T cell subsets, namely T-box
transcription factor (Tbet), GATA binding protein 3 (GATA3)
and retinoid-acid receptor-relat-ed orphan receptor gamma t
(RORyT) are all increased in children with ASD (Ahmad et al.,
2017b). These studies support the notion of distinct clusters of
ASD phenotypes characterized by immune dysfunction (Sacco
et al., 2010, 2012).
Aberrant T cell responses or decreased removal of activated
T cells can lead to autoimmune pathology (Joller et al.,
2012). CD95 is the first apoptosis signal (Fas) receptor, which
initiates apoptosis of activated T cells when they are repeatedly
exposed to antigen. It has critical importance in tolerance
and regulation, and alterations in Fas signaling may play a
role in the development of autoimmunity (Siegel and Fleisher,
1999). Reduced CD95 expression on T cells from ASD subjects
compared to controls is suggestive of decreased apoptosis of
potentially overactive T cells in ASD (Engstrom et al., 2003).
Regulatory T Cells
One of the most important immune components in the
prevention of autoimmunity is regulation, and regulatory
T cells (Tregs) play a key role in immune regulation and
homeostasis (Sakaguchi, 2004). Humans that carry mutations
in the transcription factor forkhead box P3 (FOXP3) or have
depletion in Tregs develop severe autoimmunity (Sakaguchi et al.,
1995; Miyara et al., 2005; Toubi et al., 2005; Long and Buckner,
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2011; Fujio et al., 2012). Tregs have been found to be critical for
preventing autoimmunity in murine models (Sakaguchi et al.,
1995) and a deficiency of Tregs may play a role in the development
of autoimmune disorders, including RA (Toubi et al., 2005) and
SLE (Miyara et al., 2005). Autoimmune pathology can occur
when immune regulation breaks down, disrupting tolerance
and homeostasis, and leading to an aberrant attack on self
(Lourenço and La Cava, 2011). Typically in autoimmunity, a
breakdown in tolerance will lead to the production of destructive
autoantibodies by plasma cells and self-reactive T cells with a
deficit in number or activity of Tregs (Sakaguchi, 2004). Notably,
several studies have found that Tregs or their regulatory effector
molecules are decreased in some individuals with ASD (Figure 2)
(Okada et al., 2007; Ashwood et al., 2008; Mostafa et al., 2010a).
For example, plasma TGFβ1 was significantly reduced in adult
males with Asperger’s syndrome (Okada et al., 2007) and in
children with ASD (Ashwood et al., 2008). Reduced TGFβ1
was associated with increased ASD severity and lower adaptive
and cognitive behaviors (Ashwood et al., 2008). Furthermore,
microRNAs (miRNAs) involved in controlling TGFβ1 signaling
pathways show differential expression in the cortex and serum
of individuals with ASD (Mundalil Vasu et al., 2014; Ander
et al., 2015; Huang et al., 2015). Additionally, circulating
CD4+CD25high Tregs were found to be significantly decreased
in children with ASD, with reduced frequency correlating with
severity of the disorder (Mostafa et al., 2010a). Several studies
have also shown decreased IL-10 production after stimulation of
CD4+ T cells (Jyonouchi et al., 2001, 2005, 2014; Ashwood and
Wakefield, 2006).
B Cells
Antibody production of high specificity to various antigens is
the primary role of B cells, in order to neutralize and help
eliminate pathogens. Despite the growing number of studies
identifying autoantibodies in subjects with ASD, the B cells
responsible for antibody production have been poorly studied.
Irregularities in B cell populations and antibody production have
been identified in a small number of ASD studies, although
with conflicting results. A 2011 study found increased numbers
of total (CD20+) and activated (CD38+) B cells in children
with ASD compared to age-matched controls. No differences
were seen in naïve (CD5+) B cells, thus the increase in total
cells was likely due to increased activated cells, suggesting
increased immune activation overall (Ashwood et al., 2011a).
Higher numbers of CD19/CD23 B lymphocytes were also
found in children age 3–6 recently diagnosed with regressive
autism, supporting the previous findings (Wasilewska et al.,
2012). However, Heuer et al. found no differences in total
numbers of B cells, and B cell responses to stimulation were
not different among ASD subjects compared to controls (Heuer
et al., 2012). Differences in study design and markers used (CD20
and CD19, respectively) could account for the contradictory
results. Neither marker is comprehensive for individual B cell
subsets as their expression is decreased as B cells mature
and differentiate into antibody-secreting plasma cells (Tedder,
2009). CD38 expression increases significantly upon maturation,
therefore this marker may be a better indicator of the population
of effector cells that may be responsible the production of
specific autoantibodies. Additional research is needed to further
characterize these cells, including identifying populations of
positive regulators and B-regulatory cells (Bregs), as these cells
secrete IL-10, have recently been found to play a role in the
induction of Tregs (Fujio et al., 2013), and play an important role
in the acquisition of tolerance during pregnancy (Rolle et al.,
2013).
In addition to significant levels of autoantibodies found in
individuals with ASD, atypical antibody production has been
frequently seen in ASD serum and plasma with correlations
to behaviors. Results vary and are often contradictory—these
inconsistencies may be due to small sample sizes and improper
controls such as “population standard” versus age-matched
controls residing in the same locale, and lack of adjusting for
seasonality. Comparing immunoglobulin levels across a broad
age range can produce inconsistencies, thus it is critical to
have age-matched controls. For example, an early report found
decreased circulating IgA associated with HLA-DR antigens in a
subset of ASD subjects (Warren et al., 1997), and a 2012 study
supported these findings (Wasilewska et al., 2012); however,
other studies showed no change in IgA (Heuer et al., 2008).
Ages varied widely in the Warren study (from ages 5 to 31)
and may account for discrepancy because IgA does not reach
adult levels until around age 10 (Aksu et al., 2006) whereas the
later studies were age-matched. Decreased IgA in children with
regressive ASD did not fulfill the criteria for either partial or
full IgA deficiency in the study by Wasilewska and colleagues,
and likely reflects immune dysfunction in a subset of patients
(Wasilewska et al., 2012). Heuer et al. found that decreased
plasma IgG/IgM negatively correlated with worsening behaviors
as assessed using the Autism Behaviors Checklist (ABC) (Heuer
et al., 2008). Researchers also found a significant increase in
IgG4 in ASD subjects, with a trending increase in IgG2 subtype
(Croonenberghs et al., 2002b; Enstrom A. et al., 2009). IgG4
is a blocking antibody, produced under conditions of chronic
antigen exposure and class switch to IgG4 is dependent on TH2
cytokines (IL-4/IL-13) (Aalberse et al., 2009). This is consistent
with the dynamic T cell responses found by later by Ashwood
et al. (2011c). These correlations support an association with
immune dysfunction and potentially a lack of immune regulation
in individuals with ASD.
IMPROVEMENT OF SYMPTOMS WITH THE
USE OF IMMUNE-MODULATING DRUGS
AND SUPPLEMENTS
Several clinical trials have shown the efficacy of
immunosuppressive drugs for improving behaviors in
individuals with ASD. The first study to show this relationship
used corticosteroid treatment in a 6-year-old boy with language
regression at 22 months who received a diagnosis of PDD
(pervasive developmental disorder) at age 3-1/2. After several
weeks of this treatment, the boy experienced significant gains
in expressive language and responsiveness to communication
to nearly age-appropriate levels, and reduction in stereotypical
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FIGURE 3 | Summary of Immune Evidence in ASD–is Immune Dysregulation Causing or Contributing to these Disorders? Immune findings in individuals with ASD
have grown from a few scant early studies to a plethora of extensive and varied research showing immune dysfunction that contributes to worsening behaviors.
Familial autoimmunity is a common finding within families affected by ASD. In addition, individuals with ASD have significant immune dysregulation that contribute to
altered behaviors. These individuals also suffer more so than the general population from immune-mediated comorbidities such as allergies, asthma and
gastrointestinal (GI) disturbances. Mechanistically, studies have shown that the gestational immune environment must be delicately balanced, and without such
balance neurodevelopment can be altered. Whether these immune characteristics are causal or just sequelae of the overarching disorders remain to be determined;
however, the evidence is building that the dysregulated immune response may be pathologically contributing to ASD.
echolalia (Stefanatos et al., 1995). Since then, improvements
have been seen in language ability, behaviors and motor
development in several case studies and clinical trials using
corticosteroids and immunosuppressive drugs (Mott et al., 1996;
Chez et al., 1998; Shenoy et al., 2000; Mordekar et al., 2009)
including a recent study that showed improvement in language-
specific electrophysiological brain function after treatment with
corticosteroids (Duffy et al., 2014). The effectiveness of the
anti-psychotic medication risperidone in improving stereotyped
behaviors and social withdrawal in individuals with ASD was
increased with the addition of celecoxib, a cyclooxygenase-
2 (COX-2) selective nonsteroidal anti-inflammatory drug
(Asadabadi et al., 2013). Human cord blood mononuclear
cell transplantation, alone and in combination with umbilical
mesenchymal stem cell transplantation significantly improved
behaviors in children with ASD compared to controls. These
transplanted cell types are known to have profound immune-
regulatory capabilities, suggesting that a possible mechanism of
improvements seenmay be immune-modulation (Lv et al., 2013).
These trials and cases studies, although small and specific to
select groups of ASD subjects, suggest that in some children with
ASD, immune abnormalities may be driving certain behaviors.
Nutritional or supplemental approaches may be helpful in
modulating immune function in people with ASD. Several
studies have found children with ASD to be deficient in serum
levels of vitamin D (25-hydroxycholecalciferol), and serum levels
were found to be negatively associated with language and
behavioral scores on the ABC and the Childhood Autism Rating
Scale (CARS) (Desoky et al., 2017; Saad et al., 2018), (Feng et al.,
2017). Serum vitamin D levels also negatively correlated with the
presence of anti-myelin-associated glycoprotein autoantibodies
(Mostafa and Al-Ayadhi, 2012a). This fat-soluble vitamin has
important immunomodulatory and neuroprotective functions
(Aranow, 2011; Wrzosek et al., 2013), and deficiency may be
contributing to immune and behavioral abnormalities in people
with ASD. Daily supplementation with Vitamin D, not to exceed
5,000 IU/day, was found to significantly improve behavioral
outcomes and lowered elevation of CD5 expression in children
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with ASD, supporting a role for Vitamin D in modulating the
immune system (Desoky et al., 2017; Feng et al., 2017; Saad
et al., 2018). As previously discussed, children with ASD have
altered T cell profiles, perhaps due to altered transcriptional
activity (Ahmad et al., 2017b). Similar T cell alterations have been
seen in the inbred BTBR mouse model of ASD, and a recent
study showed modulation of this transcriptional activity through
the administration of the antioxidant resveratrol, a nutritional
component found in various fruits, legumes, and grape juice.
Resveratrol increased mRNA expression of Foxp3 in spleen and
brain tissues, and increased the number of Foxp3+ T regulatory
cells in the periphery of BTBR and B6 mice. Resveratrol
also decreased expression of transcription factors associated
with inflammatory T cells, including TH17 cells. Additionally,
the nutritional compound decreased ASD associated repetitive
behaviors in BTBR mice (Bakheet et al., 2017). These studies,
offer support that immune dysfunction is driving at least some of
the pathological outcomes in subsets of people with ASD. As our
understanding of how immune dysregulation is contributing to
the pathogenesis of ASD grows, more treatments can be targeted
specifically to these mechanisms.
OUTSTANDING QUESTIONS AND
CONCLUSION
The evidence that immune dysfunction likely plays a role in
the etiology/pathophysiology of ASD is becoming substantial.
Familial autoimmunity is a common risk factor, and maternal
autoantibodies and inflammation during gestation significantly
increase the risk of having a child with ASD. Furthermore,
individuals with ASD have significant immune dysfunction and
inflammation. They also suffer from immune-mediated co-
morbidities much more often than the typically developing
population, including GI dysfunction and dysbiosis. The
presence of autoantibodies in individuals with ASD is increased,
and evidence of neuroinflammation has been substantiated both
in vivo and in post-mortem brain tissue. Although the plethora
of evidence identifying a connection between autoimmunity,
immune dysfunction, and ASD (summarized in Figure 3) is
tantalizing, it still leaves many mechanistic questions regarding
the impact of immune system dysfunction on the development
of ASD.
The most outstanding question remaining from these studies
is whether the immune dysfunction is causal or rather sequelae
of the larger disorder. The origin of the immune dysfunction
seen in many individuals with ASD and the role it plays in
the aberrant behaviors is still unknown, although many of these
studies discussed throughout this review support an association
of worsening behaviors associated with altered immune function.
Gestational influences, including maternal immune activation
and the presence of maternal autoantibodies may be contributing
to altered early neurodevelopment and immune dysfunction in
offspring, and these are supported by preclinical animal models
of both maternal immune activation and passive transfer of
autoantibodies. Interactions between the different immune cells
leading to inflammation and altered cytokine production in
people with ASD may be directly contributing to abnormal brain
development and signaling, and the ever expanding knowledge of
neuro-immune cross-talk may eventually elucidate some of the
mechanisms involved in the pathogenesis of ASD.
To date, categorizing ASD and immune dysfunction has
been a difficult task due to the heterogeneity of the disorder
and the changing diagnostic criteria; however, the recent focus
on clustering phenotypes may provide a clearer picture to
help elucidate the different factors involved in the etiologies
of these complex disorders. The immune dysfunction driving
the development of autoantibodies and overall immune
abnormalities in people with ASD remains unknown, however,
recent insights into dysbiosis causing aberrant immune system
education could be a plausible mechanism as to the origin of
immune dysfunction. Prenatal immune influences could be
driving direct and/or epigenetic changes in gene expression
responsible for altered neurodevelopment. As future studies
improve our understanding of these complex and interconnected
systems, it will allow for development of new therapies that target
immune dysfunction in ASD. Future research could focus on
interventions that improve immune parameters to help identify
mechanisms involved in development and exacerbation of ASD
symptoms. As our understanding of the involvement of the
immune system in ASD grows, it can shape future hypotheses
and research to better identify the pathological mechanisms
involved.
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